靶向致癌性m6A去甲基化酶FTO可抑制肝细胞癌肿瘤发生并增强免疫应答
该研究探讨FTO在肝细胞癌中的作用及与sEV的关系,发现FTO在患者HCC肿瘤中表达上调,通过m6A依赖方式稳定GPNMB并包装入sEV抑制CD8+ T细胞激活;FTO抑制剂CS2可抑制HCC细胞恶性功能并增强抗PD-1和索拉非尼疗效。
要点
- FTO在患者肝细胞癌肿瘤中表达上调,促进HCC细胞增殖、迁移、侵袭及体内肿瘤生长和转移。
- FTO降低GPNMB的m6A丰度,经YTHDF2稳定GPNMB,sEV-GPNMB结合CD8+ T细胞表面SDC4抑制其激活。
- FTO抑制剂CS2抑制HCC细胞恶性功能,并增强抗PD-1和索拉非尼治疗的敏感性。
核心结论
- 靶向FTO/m6A/GPNMB轴可显著抑制肿瘤生长和转移并增强免疫激活,凸显靶向FTO信号的有效抑制剂用于HCC治疗的潜力。
研究设计与样本
- 研究在体外和体内探究FTO及GPNMB在HCC进展中的功能与机制。
- 使用SDC4中和抗体评估sEV-GPNMB的意义,使用FTO抑制剂CS2检验对抗PD-1和索拉非尼治疗的影响。
主要发现
- FTO在患者HCC肿瘤中表达上调,体外促进HCC细胞增殖、迁移和侵袭,体内促进肿瘤生长和转移。
- FTO敲低增强肿瘤浸润CD8+ T细胞的激活和募集。
- GPNMB为FTO下游靶点,FTO降低GPNMB的m6A丰度,经YTHDF2稳定GPNMB免于降解。
- GPNMB被包装入HCC细胞来源的sEV,结合CD8+ T细胞表面受体SDC4,抑制CD8+ T细胞激活。
- FTO抑制剂CS2抑制HCC细胞致癌功能,并增强抗PD-1和索拉非尼治疗的敏感性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fat mass and obesity-associated protein (FTO), an eraser of N 6-methyadenosine (m6A), plays oncogenic roles in various cancers. However, its role in hepatocellular carcinoma (HCC) is unclear. Furthermore, small extracellular vesicles (sEVs, or exosomes) are critical mediators of tumourigenesis and metastasis, but the relationship between FTO-mediated m6A modification and sEVs in HCC is unknown. DESIGN: The functions and mechanisms of FTO and glycoprotein non-metastatic melanoma protein B (GPNMB) in HCC progression were investigated in vitro and in vivo. Neutralising antibody of syndecan-4 (SDC4) was used to assess the significance of sEV-GPNMB. FTO inhibitor CS2 was used to examine the effects on anti-PD-1 and sorafenib treatment. RESULTS: FTO expression was upregulated in patient HCC tumours. Functionally, FTO promoted HCC cell proliferation, migration and invasion in vitro, and tumour growth and metastasis in vivo. FTO knockdown enhanced the activation and recruitment of tumour-infiltrating CD8+ T cells. Furthermore, we identified GPNMB to be a downstream target of FTO, which reduced the m6A abundance of GPNMB, hence, stabilising it from degradation by YTH N 6-methyladenosine RNA binding protein F2. Of note, GPNMB was packaged into sEVs derived from HCC cells and bound to the surface receptor SDC4 of CD8+ T cells, resulting in the inhibition of CD8+ T cell activation. A potential FTO inhibitor, CS2, suppresses the oncogenic functions of HCC cells and enhances the sensitivity of anti-PD-1 and sorafenib treatment. CONCLUSION: Targeting the FTO/m6A/GPNMB axis could significantly suppress tumour growth and metastasis, and enhance immune activation, highlighting the potential of targeting FTO signalling with effective inhibitors for HCC therapy.
引用
- Chen A, Zhang VX, Zhang Q, et al. Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma. Gut. 2024. PMID: 38839271. doi:10.1136/gutjnl-2024-331903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。